Loading...
OTC Markets
Totals
Securities
12,253
Dollar Vol
$292.9M
Share Vol
491.7M
Trades
34,574
OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
CYDY
CytoDyn Inc.
Common Stock
0.271
0.009
3.44%
0.27 / 0.272 (14325 x 20000)
Real-Time Best Bid & Ask: 10:17am 08/06/2025
Delayed (15 Min) Trade Data: 10:02am 08/06/2025
0.2617
0.26 - 0.273
155,769
Market Cap calculated only for this class of securities.
328,530,040
Real-Time Level 2 Quote
Bid
Ask
MPID MPID | Bid Price Bid Price | Size Size | Time Time |
|---|---|---|---|
Citadel Securities | 0.27 | 14,325 | 10:16 |
OTC NQB | 0.269 | 3,275 | 10:06 |
GTS Securities LLC | 0.2631 | 15,000 | 10:01 |
CANACCORD GENUITY LLC. | 0.263 | 5,000 | 10:02 |
G1 Execution Services, LLC | 0.258 | 15,000 | 10:01 |
MPID MPID | Ask Price Ask Price | Size Size | Time Time |
|---|---|---|---|
G1 Execution Services, LLC | 0.272 | 20,000 | 10:17 |
Citadel Securities | 0.2729 | 5,800 | 10:16 |
OTC NQB | 0.275 | 2,500 | 10:06 |
GTS Securities LLC | 0.275 | 26,900 | 09:30 |
Maxim Group LLC | 0.2894 | 2,500 | 09:41 |
Trade Data
Date Date | Timestamp Timestamp | Price Price | $ Change $ Change | Volume Volume |
|---|---|---|---|---|
| 08/06/2025 | 10:03:12 | 0.271 | -0.00 | 5,970 |
| 08/06/2025 | 10:02:38 | 0.273 | 0.00 | 100 |
| 08/06/2025 | 10:02:05 | 0.2706 | -0.00 | 230 |
| 08/06/2025 | 10:01:17 | 0.273 | 0.00 | 7,848 |
| 08/06/2025 | 10:00:16 | 0.273 | 0.00 | 100 |
News
CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal CancerGlobeNewswire | 06/24/2025
CytoDyn Releases ESMO Breast Cancer Meeting PosterGlobeNewswire | 05/15/2025
Filings and Disclosure
Company Description
CytoDyn Inc. (together with its wholly owned subsidiaries, the "Company") was originally incorporated under the laws of Colorado on May 2, 2002, under the name RexRay Corporation and, effective August 27, 2015, reincorporated under the laws of Delaware. The Company is a clinical-stage biotechnology company focused on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 ("CCR5").
Videos
This company has not added any videos
Joined OTCQB 10/2014
The Company Profile data was verified by the issuer within the previous 6 months.
The company’s transfer agent has verified its outstanding shares directly to OTC Markets.
The Company’s board of directors includes at least two Independent Directors.
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.
Loading...
Symbol
OTCM
Last
56.51
Change
0.00 (0.00%)
Bid
56.41
Ask
58.00
Volume
0
Time
00:00
